Monoclonal antibody-drug conjugatePhase 3 trialInvestigational
Ladiratuzumab vedotin
How it works
Binds to a protein on prostate cancer cells and delivers a toxic payload that kills the cells.
Cancer types
Efficacy
In clinical trials, ladiratuzumab vedotin showed promising results in patients with metastatic castration-resistant prostate cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.